Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in MED?
Medgold Resources Corp: THE INVESTMENT CASE

Medgold Resources excited by potential of Serbia project ahead of drilling

Medgold has earmarked drilling to start at the Tlamino project in Serbia in August
Medgold Resources excited by potential of Serbia project ahead of drilling
Medgold is exploring in Serbia

Gold explorer Medgold Resources Corp (CVE:MED) is looking at a busy and exciting summer, as it pushes ahead with drilling and thereby potentially de-risking the Tlamino project in Serbia.

It has lined up a contractor, is going through final hurdles, and a 2,500 metre drill program is earmarked to start at the end of this summer initially to test high grade areas it has identified.

The property includes two historical showings - Liska and Barje - and the IP survey work identified an anomaly which extends to the west of the Barje outcrop for over 1km, which will also be drill tested.

Channel sampling has also thrown up high grades, for example an overall intersection of 84 metres (m) at 5.6 g/t gold at Barje.

Dan James, the president at Medgold recently told Proactive: "I haven't seen many projects around with grade like that, siting at surface. You can't walk away."

WATCH - Medgold boss on 'tantalising' potential at Tlamino after encouraging results

What assets does Medgold Resources have?

The Europe-focused group is partnered with Centerra in Portugal, which fully funds its work, and in Serbia, it has struck a strategic alliance with Fortuna Silver Mines Inc.

The main project in Portugal was Boticas but after several years, and having not discovered a 1mln ounce target, the firm has stepped back efforts in the country to focused wholly on Serbia.

There, Fortuna, which has a 24% stake in Medgold and it's the largest shareholder,  has chosen  Tlamino as the first project to option.

Essentially, the deal sees Fortuna financing exploration on a select small portfolio of projects and then electing or not to progress further with whatever looks good in a formal joint venture

It can earn up to 70% of two chosen projects by spending $8mln on exploration and completing a preliminary economic assessment (PEA).

Registering interest in many licences.

Notably, Medgold already has six licences granted in Serbia and had registered interest in around 20 more, so  it really has hit the ground aggressively in the country, which is currently enjoying a  new wave of mining industry interest.

Capital Network's mining analyst Sam Catalano says he likes the fact that Medgold has joined with a larger partner across its Serbian asset base to ensure it’s a ‘well-funded exploration vehicle’.

"As a broad comment, this can provide potential Medgold investors with some comfort that they will not be asked to contribute meaningful equity to support exploration efforts.

"The flip-side is that to some extent investors upside in the main projects is capped (typically at ~30% of asset value), however, in a time of low equity prices in the sector, and general difficulty for early stage exploration funding, we believe this shows good savvy from the management team to push their efforts forward."

View full MED profile View Profile

Medgold Resources Corp Timeline

Related Articles

November 01 2017
Pan Asia Metals is building strength in depth in South East Asia
August 21 2018
Mkango is now well underway with the largest drill programme to date at Songwe
Cobalt sample on the periodic table
May 23 2018
One of Australia’s few potential cobalt producers from sulphide-based deposits, where cobalt production is underpinned by copper and gold.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use